1465-74-3

Basic information

• Product Name: 2-[10-(octahydroisoquinolin-2(1H)-yl)decyl]-1,2-dihydroisoquinoline
• CAS NO: 1465-74-3
• Molecular Formula: C₂₈H₄₄N₂
• Molecular Weight: 408.6624
• Mol File: 1465-74-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 539.2°C at 760 mmHg
• Flash Point: 240.6°C
• Density: 0.982g/cm³
• Vapor Pressure: 1.08E-11mmHg at 25°C
• Refractive Index: 1.533
• CAS DataBase Reference: 2-[10-(octahydroisoquinolin-2(1H)-yl)decyl]-1,2-dihydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[10-(octahydroisoquinolin-2(1H)-yl)decyl]-1,2-dihydroisoquinoline(1465-74-3)
• EPA Substance Registry System: 2-[10-(octahydroisoquinolin-2(1H)-yl)decyl]-1,2-dihydroisoquinoline(1465-74-3)

Safety Data

• Hazardous Substances Data: 1465-74-3(Hazardous Substances Data)

Usage

Class

Dihydroisoquinolines

Structure

A complex organic molecule containing a long hydrocarbon chain and two isoquinoline rings

Functional groups

10-carbon chain connected to one of the isoquinoline rings and a 1,2-dihydroisoquinoline group on the other

Properties

Unique structure and specific properties due to its complex structure and functional groups

Applications

Useful in the fields of pharmaceuticals, materials science, and organic synthesis

Potential

Intricate structure and functional groups offer potential for further research and development in the field of organic chemistry and drug discovery.

Upstream product

• 119-65-3 isoquinoline 
• 4101-68-2 1,10-dibromodecane 

Relevant articles and documents

Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage - Implications for early Myasthenia gravis treatment

Inhibitors of acetylcholinesterase are compounds widely used in the treatment of various diseases, such as Alzheimer's disease, glaucoma and Myasthenia gravis (MG). Compounds used in the therapy of MG posses a positive charge in the molecule to ensure peripheral effect of action and minimal blood-brain barrier penetration. The most prescribed carbamate inhibitors are however known for many severe side effects related to the carbamylation of AChE. This paper describes preparation and in vitro evaluation of 20 newly prepared bis-isoquinolinium inhibitors of potential concern for MG. The newly prepared compounds were evaluated in vitro on human recombinant AChE and human plasmatic butyrylcholinesterase (BChE). Their inhibitory ability was expressed as IC 50 and compared to chosen standards ambenonium dichloride, edrophonium chloride, BW284c51 and ethopropazine hydrochloride. Three novel compounds presented promising inhibition (in nM range) of both enzymes in vitro better or similar to edrophonium and BW284c51, but worse to ambenonium. The novel inhibitors did not present higher selectivity toward AChE or BChE. The kinetic assay confirmed non-competitive inhibition of hAChE by two selected promising novel compounds. Two newly prepared compounds were also chosen for docking studies that confirmed apparent π-π or π-cationic interactions aside the cholinesterases catalytic sites. The SAR findings were discussed.

Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release

A series of tertiary amine analogs derived from lead azaaromatic quaternary ammonium salts has been designed and synthesized. The preliminary structure-activity relationships of these new analogs suggest that such tertiary amine analogs, which potently inhibit nicotine-evoked dopamine release from rat striatum, represent drug-like inhibitors of α6-containing nicotinic acetylcholine receptors. The bis-tertiary amine analog 7 exhibited an IC 50 of 0.95 nM, while the tris-tertiary amine analog 19 had an IC 50 of 0.35 nM at nAChRs mediating nicotine-evoked dopamine release.